MX2013008374A - Apolipoproteina a-iv como un peptido antidiabetico. - Google Patents

Apolipoproteina a-iv como un peptido antidiabetico.

Info

Publication number
MX2013008374A
MX2013008374A MX2013008374A MX2013008374A MX2013008374A MX 2013008374 A MX2013008374 A MX 2013008374A MX 2013008374 A MX2013008374 A MX 2013008374A MX 2013008374 A MX2013008374 A MX 2013008374A MX 2013008374 A MX2013008374 A MX 2013008374A
Authority
MX
Mexico
Prior art keywords
subject
methods
need
diabetes mellitus
apolipoprotein
Prior art date
Application number
MX2013008374A
Other languages
English (en)
Other versions
MX342020B (es
Inventor
Fei Wang
Patrick Tso
Sean Davidson
Stephen Woods
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of MX2013008374A publication Critical patent/MX2013008374A/es
Publication of MX342020B publication Critical patent/MX342020B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Abstract

Se describen métodos para tratar diabetes mellitus tipo dos en un sujeto en necesidad del mismo y composiciones farmacéuticas para el tratamiento de diabetes mellitus tipo dos; los métodos incluyen administrar una cantidad eficaz de apolipoproteína A-IV al sujeto; la composición farmacéutica incluye apolipoproteína A-lV formulada para administración a un sujeto para el tratamiento de diabetes mellitus tipo dos; también se describen métodos para restaurar sustancialmente la tolerancia a la glucosa en un sujeto en necesidad de los mismos a un nivel normal y métodos para disminuir las concentraciones de glucosa sanguínea en un sujeto en necesidad de los mismos.
MX2013008374A 2011-01-19 2012-01-19 Apolipoproteina a-iv como un peptido antidiabetico. MX342020B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434196P 2011-01-19 2011-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide

Publications (2)

Publication Number Publication Date
MX2013008374A true MX2013008374A (es) 2013-12-06
MX342020B MX342020B (es) 2016-09-08

Family

ID=45755499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008374A MX342020B (es) 2011-01-19 2012-01-19 Apolipoproteina a-iv como un peptido antidiabetico.

Country Status (13)

Country Link
US (2) US9051394B2 (es)
EP (1) EP2665485B1 (es)
JP (1) JP2014504601A (es)
KR (1) KR20140071272A (es)
CN (1) CN103391786B (es)
AU (1) AU2012207301B2 (es)
CA (1) CA2823712A1 (es)
EA (1) EA028218B1 (es)
ES (1) ES2620404T3 (es)
IL (1) IL227207B (es)
MX (1) MX342020B (es)
SG (1) SG191992A1 (es)
WO (1) WO2012100010A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010347724B2 (en) * 2010-03-12 2016-06-23 Exxonmobil Upstream Research Company Dynamic grouping of domain objects via smart groups
JP2014504601A (ja) 2011-01-19 2014-02-24 ユニバーシティ・オブ・シンシナティ 抗糖尿病ペプチドとしてのアポリポタンパク質ａｉｖ
JP6310398B2 (ja) 2012-01-19 2018-04-11 ユニバーシティ・オブ・シンシナティ 非グリコシル化アポリポタンパク質ａ−ｉｖを用いて糖尿病を処置する方法
AU2013295721B2 (en) * 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
WO2001077124A2 (en) * 2000-04-05 2001-10-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the apoa4 gene
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US20110107439A1 (en) 2008-03-21 2011-05-05 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103833713B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
JP2014504601A (ja) 2011-01-19 2014-02-24 ユニバーシティ・オブ・シンシナティ 抗糖尿病ペプチドとしてのアポリポタンパク質ａｉｖ
JP6310398B2 (ja) 2012-01-19 2018-04-11 ユニバーシティ・オブ・シンシナティ 非グリコシル化アポリポタンパク質ａ−ｉｖを用いて糖尿病を処置する方法
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法

Also Published As

Publication number Publication date
ES2620404T3 (es) 2017-06-28
CN103391786A (zh) 2013-11-13
MX342020B (es) 2016-09-08
AU2012207301A1 (en) 2013-08-01
WO2012100010A1 (en) 2012-07-26
SG191992A1 (en) 2013-08-30
EA028218B1 (ru) 2017-10-31
CN103391786B (zh) 2016-06-22
US9266941B2 (en) 2016-02-23
EA201391063A1 (ru) 2013-12-30
US20140005107A1 (en) 2014-01-02
AU2012207301B2 (en) 2016-05-19
KR20140071272A (ko) 2014-06-11
EP2665485B1 (en) 2017-01-11
AU2012207301A8 (en) 2013-08-29
EP2665485A1 (en) 2013-11-27
AU2012207301A2 (en) 2015-03-26
CA2823712A1 (en) 2012-07-26
US9051394B2 (en) 2015-06-09
JP2014504601A (ja) 2014-02-24
US20150252095A1 (en) 2015-09-10
IL227207B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX2013008374A (es) Apolipoproteina a-iv como un peptido antidiabetico.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
TN2016000500A1 (en) Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
MX2013009948A (es) Composiciones de insulina y cromo para el tratamiento y prevencion de diabetes, hipoglucemia y alteraciones relacionadas.
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
IN2014MN01442A (es)
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
RU2014152196A (ru) Способ улучшения функции печени
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
WO2012091425A3 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань

Legal Events

Date Code Title Description
FG Grant or registration